Microbiome

Challenge: Our client, a mid-cap pharma, was planning to extend its portfolio in the gastrointestinal (GI) disease space. It was considering microbiome-based approaches, specifically live...

Challenge: A biopharma company asked Alacrita to provide expert input on the clinical development of a microbiome therapeutic (LBP, live biotherapeutic product) in the context of first line and...

Challenge: A clinical stage microbiome company was developing a microbiome therapeutic for the treatment of recurrent C. Difficle infection (rCDI). The company was progressing through clinical...